Publikation:

Challenges and Scientific Prospects of the Newest Generation of mRNA-Based Vaccines against SARS-CoV-2

Lade...
Vorschaubild

Dateien

Calina_2-1vje3xdbqimqh7.pdf
Calina_2-1vje3xdbqimqh7.pdfGröße: 1.15 MBDownloads: 205

Datum

2021

Autor:innen

Calina, Daniela
Hernández, Antonio F.
Egorov, Alexey M.
Izotov, Boris Nikolaevich
Nikolouzakis, Taxiarchis Konstantinos
Tsatsakis, Aristidis
Vlachoyiannopoulos, Panayiotis G.
Docea, Anca Oana

Herausgeber:innen

Kontakt

ISSN der Zeitschrift

Electronic ISSN

ISBN

Bibliografische Daten

Verlag

Schriftenreihe

Auflagebezeichnung

ArXiv-ID

Internationale Patentnummer

Link zur Lizenz

Angaben zur Forschungsförderung

Projekt

Open Access-Veröffentlichung
Open Access Gold
Core Facility der Universität Konstanz

Gesperrt bis

Titel in einer weiteren Sprache

Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published

Erschienen in

Life. MDPI. 2021, 11(9), 907. eISSN 2075-1729. Available under: doi: 10.3390/life11090907

Zusammenfassung

In the context of the current COVID-19 pandemic, traditional, complex and lengthy methods of vaccine development and production would not have been able to ensure proper management of this global public health crisis. Hence, a number of technologies have been developed for obtaining a vaccine quickly and ensuring a large scale production, such as mRNA-based vaccine platforms. The use of mRNA is not a new concept in vaccine development but has leveraged on previous knowledge and technology. The great number of human resources and capital investements for mRNA vaccine development, along with the experience gained from previous studies on infectious diseases, allowed COVID-19 mRNA vaccines to be developed, conditionally approved and commercialy available in less than one year, thanks to decades of basic research. This review critically presents and discusses the COVID-19 mRNA vaccine-induced immunity, and it summarizes the most common anaphylactic and autoimmune adverse effects that have been identified until now after massive vaccination campaigns.

Zusammenfassung in einer weiteren Sprache

Fachgebiet (DDC)
570 Biowissenschaften, Biologie

Schlagwörter

COVID-19 pandemic; public health; coronaviruses; mRNA vaccines; side effects

Konferenz

Rezension
undefined / . - undefined, undefined

Forschungsvorhaben

Organisationseinheiten

Zeitschriftenheft

Zugehörige Datensätze in KOPS

Zitieren

ISO 690CALINA, Daniela, Antonio F. HERNÁNDEZ, Thomas HARTUNG, Alexey M. EGOROV, Boris Nikolaevich IZOTOV, Taxiarchis Konstantinos NIKOLOUZAKIS, Aristidis TSATSAKIS, Panayiotis G. VLACHOYIANNOPOULOS, Anca Oana DOCEA, 2021. Challenges and Scientific Prospects of the Newest Generation of mRNA-Based Vaccines against SARS-CoV-2. In: Life. MDPI. 2021, 11(9), 907. eISSN 2075-1729. Available under: doi: 10.3390/life11090907
BibTex
@article{Calina2021-09Chall-55013,
  year={2021},
  doi={10.3390/life11090907},
  title={Challenges and Scientific Prospects of the Newest Generation of mRNA-Based Vaccines against SARS-CoV-2},
  number={9},
  volume={11},
  journal={Life},
  author={Calina, Daniela and Hernández, Antonio F. and Hartung, Thomas and Egorov, Alexey M. and Izotov, Boris Nikolaevich and Nikolouzakis, Taxiarchis Konstantinos and Tsatsakis, Aristidis and Vlachoyiannopoulos, Panayiotis G. and Docea, Anca Oana},
  note={Article Number: 907}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/55013">
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/55013/1/Calina_2-1vje3xdbqimqh7.pdf"/>
    <dc:creator>Hernández, Antonio F.</dc:creator>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/55013/1/Calina_2-1vje3xdbqimqh7.pdf"/>
    <dc:contributor>Izotov, Boris Nikolaevich</dc:contributor>
    <dc:contributor>Tsatsakis, Aristidis</dc:contributor>
    <dc:rights>Attribution 4.0 International</dc:rights>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-09-24T08:36:20Z</dcterms:available>
    <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/55013"/>
    <dcterms:abstract xml:lang="eng">In the context of the current COVID-19 pandemic, traditional, complex and lengthy methods of vaccine development and production would not have been able to ensure proper management of this global public health crisis. Hence, a number of technologies have been developed for obtaining a vaccine quickly and ensuring a large scale production, such as mRNA-based vaccine platforms. The use of mRNA is not a new concept in vaccine development but has leveraged on previous knowledge and technology. The great number of human resources and capital investements for mRNA vaccine development, along with the experience gained from previous studies on infectious diseases, allowed COVID-19 mRNA vaccines to be developed, conditionally approved and commercialy available in less than one year, thanks to decades of basic research. This review critically presents and discusses the COVID-19 mRNA vaccine-induced immunity, and it summarizes the most common anaphylactic and autoimmune adverse effects that have been identified until now after massive vaccination campaigns.</dcterms:abstract>
    <dc:creator>Izotov, Boris Nikolaevich</dc:creator>
    <dc:contributor>Docea, Anca Oana</dc:contributor>
    <dc:creator>Docea, Anca Oana</dc:creator>
    <dcterms:issued>2021-09</dcterms:issued>
    <dc:contributor>Egorov, Alexey M.</dc:contributor>
    <dc:creator>Egorov, Alexey M.</dc:creator>
    <dc:creator>Vlachoyiannopoulos, Panayiotis G.</dc:creator>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:contributor>Calina, Daniela</dc:contributor>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:contributor>Nikolouzakis, Taxiarchis Konstantinos</dc:contributor>
    <dc:creator>Hartung, Thomas</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-09-24T08:36:20Z</dc:date>
    <dc:language>eng</dc:language>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:creator>Calina, Daniela</dc:creator>
    <dc:contributor>Hartung, Thomas</dc:contributor>
    <dc:creator>Nikolouzakis, Taxiarchis Konstantinos</dc:creator>
    <dc:creator>Tsatsakis, Aristidis</dc:creator>
    <dc:contributor>Vlachoyiannopoulos, Panayiotis G.</dc:contributor>
    <dc:contributor>Hernández, Antonio F.</dc:contributor>
    <dcterms:title>Challenges and Scientific Prospects of the Newest Generation of mRNA-Based Vaccines against SARS-CoV-2</dcterms:title>
  </rdf:Description>
</rdf:RDF>

Interner Vermerk

xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter

Kontakt
URL der Originalveröffentl.

Prüfdatum der URL

Prüfungsdatum der Dissertation

Finanzierungsart

Kommentar zur Publikation

Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Ja
Begutachtet
Unbekannt
Diese Publikation teilen